Literature DB >> 2729926

High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay.

G G Granich1, D J Krogstad, J D Connor, K L Desrochers, C Sherwood.   

Abstract

The use of high-performance liquid chromatography (HPLC) to measure ribavirin in serum and other biological fluids has been limited by endogenous interfering substances. We report an HPLC procedure based on the extraction of ribavirin from serum, plasma, or cerebrospinal fluid with a boronate affinity gel, which uses a 3-methylcytidine internal standard. This assay is sensitive (to 0.4 microM), specific (no interference with 34 commonly prescribed drugs), reproducible (coefficients of variation from 5.4 to 22.4%), and linear (r = 0.999) over the range of clinically relevant concentrations in serum (from 0.5 to 50.0 microM). It also correlates well with the ribavirin radioimmunoassay (r = 0.992). This HPLC assay should be useful for measuring ribavirin in serum and other body fluids during clinical trials.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2729926      PMCID： PMC171484          DOI： 10.1128/AAC.33.3.311

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  High-performance liquid chromatographic separation and quantitation of nucleosides in urine and some other biological fluids.

Authors:  G E Davis; R D Suits; K C Kuo; C W Gehrke; T P Waalkes; E Borek
Journal:  Clin Chem       Date:  1977-08       Impact factor: 8.327

2.  Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome.

Authors:  R B Roberts; O L Laskin; J Laurence; D Scavuzzo; H W Murray; Y T Kim; J D Connor
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

3.  Determination of inosine and adenosine in human plasma using high-performance liquid chromatography and a boronate affinity gel.

Authors:  E H Pfadenhauer; S D Tong
Journal:  J Chromatogr       Date:  1979-04-11

4.  High-performance liquid chromatographic determination of 2-beta-D-ribofuranosylthiazole-4-carboxamide in urine and plasma.

Authors:  B Chandrasekaran; B Ardalan
Journal:  J Chromatogr       Date:  1983-08-12

5.  Bioassay system for determining ribavirin levels in human serum and urine.

Authors:  D F Smee; R W Sidwell; B B Barnett; R S Spendlove
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

6.  Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

Authors:  J J Kirsi; J A North; P A McKernan; B K Murray; P G Canonico; J W Huggins; P C Srivastava; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

7.  Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin.

Authors:  R K Austin; P E Trefts; M Hintz; J D Connor; M F Kagnoff
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

8.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

9.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

Authors:  C B Hall; J T McBride; E E Walsh; D M Bell; C L Gala; S Hildreth; L G Ten Eyck; W J Hall
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

10.  Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.

Authors:  B E Gilbert; S Z Wilson; V Knight; R B Couch; J M Quarles; L Dure; N Hayes; G Willis
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191
View more
  8 in total

1.  Weibull function fits to pharmacokinetic data of ribavirin in man.

Authors:  X D Liu; L Xie; K Q Han; G Q Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

2.  High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.

Authors:  M Homma; A L Jayewardene; J Gambertoglio; F Aweeka
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood.

Authors:  Yoichi Inoue; Masato Homma; Yasushi Matsuzaki; Minoru Shibata; Takuya Matsumura; Takayoshi Ito; Keiji Mitamura; Naomi Tanaka; Yukinao Kohda
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  HPLC-MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEM ss cells.

Authors:  Margarita Meléndez; Osvaldo Rosario; Beatriz Zayas; José F Rodríguez
Journal:  J Pharm Biomed Anal       Date:  2009-02-13       Impact factor: 3.935

5.  Ribavirin quantification in combination treatment of chronic hepatitis C.

Authors:  Sylvie Larrat; Françoise Stanke-Labesque; Agnès Plages; Jean-Pierre Zarski; Germain Bessard; Claude Souvignet
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.

Authors:  Francois-Ludovic Sauvage; Francoise Stanke-Labesque; Marie-Claude Gagnieu; Jean-Francois Jourdil; Gerard Babany; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681

7.  Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.

Authors:  Harel Dahari; Marianthi Markatou; Marija Zeremski; Ivan Haller; Ruy M Ribeiro; Teresa Licholai; Alan S Perelson; Andrew H Talal
Journal:  J Hepatol       Date:  2007-02-22       Impact factor: 25.083

8.  Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.

Authors:  Ottavia Giampaoli; Fabio Sciubba; Elisa Biliotti; Mariangela Spagnoli; Riccardo Calvani; Alberta Tomassini; Giorgio Capuani; Alfredo Miccheli; Gloria Taliani
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.